Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin

Table 3

Unique multispectrum coverage of levonadifloxacin.

Spectrum of activity of levonadifloxacin	Organisms
Excellent Gram-positive bacteria coverage	(i) Staphylococcus aureus: MSSA, MRSA, QRSA, VRSA
	(ii) Coagulase-negative staphylococci
	(iii) Staphylococcus epidermidis
	(iv) Streptococcus pneumoniae
	(v) Streptococcus pyogenes
	(vi) Streptococcus agalactiae
	(vii) Viridans group streptococci
Quinolone sensitive Gram-negative (at par with ciprofloxacin)	(i) Escherichia coli
	(ii) Klebsiella spp.
	(iii) Enterobacter spp.
	(iv) Citrobacter spp.
	(v) Proteus spp.
	vi) Providencia spp.
	(vii) Pseudomonas aeruginosa
	(viii) Moraxella catarrhalis
	(ix) Haemophilus influenzae
Good anaerobic coverage	(i) Clostridium difficile
	(ii) Clostridium perfringens
	(iii) Cutibacterium (Propionibacterium) acnes
	(iv) Peptostreptococcus spp.
Good atypical bacteria coverage	(i) Mycoplasma
	(ii) Chlamydia pneumoniae
	(iii) Chlamydia trachomatis
	(iv) Legionella pneumophila
	(v) Ureaplasma

MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus; QRSA: quinolone-resistant Staphylococcus aureus; VRSA: vancomycin-resistant Staphylococcus aureus.